Summary
This prediction ended on 17.09.24 with a price of €6.29. With a performance of 5.71%, the BUY prediction by ShortPayable90 for Evotec SE closed with a slight gain. ShortPayable90 has 50% into this predictionEvotec is a German-based biotech company that provides drug discovery and development solutions to pharmaceutical and biotechnology companies. The company operates in the fields of neuroscience, immunology, oncology, and infectious diseases, and its services include hit identification, target validation, and preclinical and clinical development. Evotec has partnerships with major pharmaceutical companies and has developed its own pipeline of drugs, with a focus on developing treatments for conditions such as Alzheimer's disease and diabetes. The company is listed on the Frankfurt and NASDAQ stock exchanges and has a market capitalization of approximately €5.5 billion.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Evotec SE | -2.439% | -2.439% |
| iShares Core DAX® | -1.471% | 1.895% |
| iShares Nasdaq 100 | -0.486% | 4.395% |
| iShares Nikkei 225® | -2.115% | 2.450% |
| iShares S&P 500 | 0.394% | 3.118% |
Comments by ShortPayable90 for this prediction
In the thread Trading Evotec AG
Die von ShortPayable90 gewählte maximale Laufzeit wurde überschritten